Stallergenes Greer

Stallergenes Greer International AG is a global biopharmaceutical company headquartered in Baar, Switzerland, specializing in the diagnosis and treatment of allergies^[2] through allergen immunotherapy.^[3]

Stallergenes Greer

Company type	Private
Industry	Pharmaceutical industry
Founded	2015; 10 years ago (2015)
Headquarters	Baar, Switzerland
Key people	Cyrus Jilla (Chairman), Andreas Amrein (Chief Executive Officer)
Revenue	€ 277 million (2018) [1]
Net income	12,8 M€ (2018)
Number of employees	1129 (2023)

Stallergenes Greer International AG^[4] is the parent company of Greer Laboratories, Inc.^[5] (registered office in the U.S.) and Stallergenes S.A.S. (registered office in France).^[6]

With 1129 employees in 2023,^[7] Stallergenes Greer operates in 21 countries and 44 countries including the distribution network.^[8]

Stallergenes Greer's core manufacturing facilities are located both in Europe (Antony and Amilly in France), in the USA (Lenoir, NC; Mathiston, MI; and San Diego, CA), and in Canada (Dutton, ON).^[9]

History

Stallergenes was founded in 1962 by Institut Mérieux ^{[10][11][12][13]} In 2015, Stallergenes and Greer Laboratories Inc. merged to form Stallergenes Greer, "a worldwide leader in allergy immunotherapy".^[14][15]

Greer was founded by R.T. Greer, a collector of source materials (i.e.: roots, herbs, pollens) in 1904.^[16]

Stallergenes Greer is a privately held company owned by B-Flexion (ex Waypoint Capital), chaired by Ernesto Bertarelli.^[17]

Activity

Stallergenes Greer is specialised in allergy immunotherapy treatments. It includes Name Patient Products (NPP) which are allergen products, prepared in accordance with prescriptions for individual patients.^[18]

The product portfolio covers different segments including sublingual products (Staloral®, Oralair®, Actair®), subcutaneous products (Alustal®/Albey®), oral immunotherapy (Palforzia)^[19], allergen extracts available as a bulk extract or NPP, veterinary products, testing supplies, source materials and other supplies like sterile diluents, sterile empty vials.

Governance

The board of directors includes:^[20][21]

• Cyrus Jilla, chairman
• Michele Antonelli
• Giampero De Luca
• Nithya Desikan
• Ranjani Kearsley
• Andreas Amrein, chief executive officer^[22]

A pharmaceutical and clinical development programme

Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies. ^{[citation needed][23]}

Oralair is the first sublingual immunotherapy tablet resulting from this programme. Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.^{[citation needed][24][25]}

The second project in this programme is the house dust mite immunotherapy tablet Actair which is marketed in Japan, Australia, and New Zealand,^[26][27] and South Korea under the brand name Actair and in Germany under the brand name Orylmyte.^[28]

In 2021, Stallergenes Greer is partnering with Aptar Pharma to develop a novel connected device for allergen immunotherapy treatment delivery. It will contribute to improving adherence, thus optimising treatment outcomes.^[29]